Yuhua Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuhua Zhu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Chen Yan
Department of Rheumatology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, People’s Republic of China
1 shared publication- Dao-Quan Tang
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China
1 shared publication - Lan Luo
School of Medical Technology, Xuzhou Medical University, Xuzhou City, People’s Republic of China
1 shared publication Liqi Luo
The First Clinical College of Xuzhou Medical University, Xuzhou, People’s Republic of China
1 shared publicationPeiyan Zhu
The First Clinical College of Xuzhou Medical University, Xuzhou, People’s Republic of China
1 shared publication- Quangang Chen
Xuzhou Medical University
1 shared publication
Latest Publications
- 3 March 2026
- Published by Springer Nature in Human Cell
- Vol. 39 (3) , 50
Herbacetin alleviates acute doxorubicin cardiotoxicity via regulating the ERK1/2-FOXO3a signaling pathway
Doxorubicin (DOX) is a commonly prescribed chemotherapeutic regimen, but its practice is challenged by cardiotoxicity risks. Herbacetin (HBT), a bioactive flavonoid compound, has demonstrated anti-oxidative, anti-inflammation, and anti-tumor properties. This study aimed to evaluate the protective effects of HBT against DOX cardiotoxicity along with the underlying mechanisms. In vitro, HBT enhanced cell survival, prevented DNA damage, reduced mitochondrial ROS, and maintained mitochondrial integrity in DOX-treated cardiomyocytes. Using an acute DOX cardiotoxicity rat model, HBT prevented DOX-induced declined cardiac function and reversed cardiac remodeling depicted by increased cell size. RNA sequence analysis of PBS-, DOX-, and DOX + HBT-treated H9c2 cardiomyocytes suggested the involvement of the MAPK signaling pathway in cardioprotective effects of HBT. Specifically, the level of phosphorylated ERK1/2 was increased in DOX-treated cardiomyocytes, which declined in the presence of HBT. The decreased level of FOXO3a (downstream factor of ERK1/2) by DOX was further restored by HBT. Lastly, the knockdown of FOXO3a abrogated the cardioprotective benefits of HBT. Our data suggest that HBT mitigates acute DOX cardiotoxicity via regulating the ERK1/2-FOXO3a signaling pathway, highlighting its potential as a novel therapeutic agent against DOX cardiotoxicity. Graphical abstract
- 3 March 2026
- Published by Springer Nature in Human Cell
- Vol. 39 (3) , 50
Herbacetin alleviates acute doxorubicin cardiotoxicity via regulating the ERK1/2-FOXO3a signaling pathway
Doxorubicin (DOX) is a commonly prescribed chemotherapeutic regimen, but its practice is challenged by cardiotoxicity risks. Herbacetin (HBT), a bioactive flavonoid compound, has demonstrated anti-oxidative, anti-inflammation, and anti-tumor properties. This study aimed to evaluate the protective effects of HBT against DOX cardiotoxicity along with the underlying mechanisms. In vitro, HBT enhanced cell survival, prevented DNA damage, reduced mitochondrial ROS, and maintained mitochondrial integrity in DOX-treated cardiomyocytes. Using an acute DOX cardiotoxicity rat model, HBT prevented DOX-induced declined cardiac function and reversed cardiac remodeling depicted by increased cell size. RNA sequence analysis of PBS-, DOX-, and DOX + HBT-treated H9c2 cardiomyocytes suggested the involvement of the MAPK signaling pathway in cardioprotective effects of HBT. Specifically, the level of phosphorylated ERK1/2 was increased in DOX-treated cardiomyocytes, which declined in the presence of HBT. The decreased level of FOXO3a (downstream factor of ERK1/2) by DOX was further restored by HBT. Lastly, the knockdown of FOXO3a abrogated the cardioprotective benefits of HBT. Our data suggest that HBT mitigates acute DOX cardiotoxicity via regulating the ERK1/2-FOXO3a signaling pathway, highlighting its potential as a novel therapeutic agent against DOX cardiotoxicity. Graphical abstract
- Top Cited PapersOpen Access
- 23 August 2018
- Published by MDPI AG in Biomolecules
- Vol. 8 (3) , 80
Research Progress on the Relationship between Atherosclerosis and Inflammation
Atherosclerosis is a chronic inflammatory disease; unstable atherosclerotic plaque rupture, vascular stenosis, or occlusion caused by platelet aggregation and thrombosis lead to acute cardiovascular disease. Atherosclerosis-related inflammation is mediated by proinflammatory cytokines, inflammatory signaling pathways, bioactive lipids, and adhesion molecules. This review discusses the effects of inflammation and the systemic inflammatory signaling pathway on atherosclerosis, the role of related signaling pathways in inflammation, the formation of atherosclerosis plaques, and the prospects of treating atherosclerosis by inhibiting inflammation.
- 23 August 2018
- Published by MDPI AG in Biomolecules
- Vol. 8 (3) , 80
Top Cited PapersOpen AccessResearch Progress on the Relationship between Atherosclerosis and Inflammation
Atherosclerosis is a chronic inflammatory disease; unstable atherosclerotic plaque rupture, vascular stenosis, or occlusion caused by platelet aggregation and thrombosis lead to acute cardiovascular disease. Atherosclerosis-related inflammation is mediated by proinflammatory cytokines, inflammatory signaling pathways, bioactive lipids, and adhesion molecules. This review discusses the effects of inflammation and the systemic inflammatory signaling pathway on atherosclerosis, the role of related signaling pathways in inflammation, the formation of atherosclerosis plaques, and the prospects of treating atherosclerosis by inhibiting inflammation.